BioMarin Pharmaceutical | BMRN - Market Capitalization


BioMarin Pharmaceutical reported $11.15B in Market Capitalization this October of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amgen USD 195.44B 5.55B Jun/2026
Bayer EUR 47.56B 8.87B Jun/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Incyte USD 24.6B 1.95B Sep/2026
Insmed USD 24.93B 1.82B Sep/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 113.52B 3.82B Mar/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
United Therapeutics USD 23B 2.19B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026